LAE-32

LAE-32
Clinical data

Routes of administration	Oral
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
IUPAC name (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
Synonyms	LAE, Lysergic acid ethylamide, d-lysergic acid ethylamide, d-ethyllysergamide,
CAS Number	478-99-9^Y
PubChem (CID)	101704
ChemSpider	19975296^Y
Chemical and physical data
Formula	C₁₈H₂₁N₃O
Molar mass	295.378 g/mol
3D model (Jmol)	Interactive image
SMILES CCNC(=O)[C@@H]2/C=C1/c3cccc4ncc(C[C@H]1N(C)C2)c34
InChI InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1^Y Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N^Y
(verify)

D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine. It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but in schizophrenic people it allows them to remain indifferent to their disorder.^[1]

Hallucinogens

Psychedelics
(5-HT_2A
agonists)

Lyserg‐
amides

Phenethyl‐
amines

2C-*	2C-B 2C-B-AN 2C-C 2C-CP 2C-D 2C-E 2C-EF 2C-F 2C-G 2C-I 2C-iP 2C-N 2C-O 2C-O-4 2C-P 2C-T 2C-T-2 2C-T-3 2C-T-4 2C-T-7 2C-T-8 2C-T-13 2C-T-15 2C-T-16 2C-T-17 2C-T-19 2C-T-21 2C-T-21.5 2C-T-22 2C-T-27 2C-T-28 2C-TFM 2C-YN TMA-2

HOT-*	HOT-2 HOT-7 HOT-17

25-NB (excludes FLY)	-NBF: 25B-NBF 25C-NBF 25I-NBF -NBOH: 25B-NBOH 25C-NBOH 25CN-NBOH 25I-NBOH -NBMD: 25B-NBMD 25C-NBMD 25I-NB34MD 25I-NBMD -NBOMe: 25B-NBOMe 25C-NBOMe 25CN-NBOMe 25D-NBOMe 25E-NBOMe 25F-NBOMe 25G-NBOMe 25I-NBOMe 25N-NBOMe 25P-NBOMe 25TFM-NBOMe

Subst. mescaline	2-Bromomescaline Allylescaline Asymbescaline Buscaline Cyclopropylmescaline Difluoromescaline Difluoroescaline Escaline Fluoroproscaline Isobuscaline Isoproscaline Mescaline Metaescaline Methallylescaline Proscaline Trifluoroescaline Trifluoromescaline

DO*	(DOT) Aleph DOB DOC DOEF DOET DOF DOI DOiPR DOM DON DOPR DOTFM MEM

3C-*	3C-AL 3C-BZ 3C-DFE 3C-E 3C-P

4C-*	4C-B 4C-D 4C-T-2

FLY	2CBFly-NBOMe 2C-B-DragonFLY 2C-B-BUTTERFLY 2C-B-FLY Bromo-DragonFLY DOB-FLY TFMFly

MD*	DMMDA DMMDA-2 Lophophine MDA MMDA MMDA-2 MMDA-3a MMDMA

Others	βk-2C-B βk-2C-I 2CB-Ind 2CD-5EtO 2CBCB-NBOMe 2-TOM 3-TE 3-TM 4-TE 4-TM 5-TOET 5-TOM BOB BOD DESOXY DMBMPP DMCPA Fenfluramine Ganesha Jimscaline Macromerine MMA NBOMe-mescaline TCB-2 Thioproscaline TOMSO TMA

Piperazines

Tryptamines

Sub. Trypt.	4,5-DHP-α-MT 5-MeO-α-ET 5-MeO-α-MT α-ET α-MT

*-DMT	4,5-DHP-DMT 2,N,N-TMT 4-AcO-DMT 4-HO-5-MeO-DMT 4,N,N-TMT 4-Propionyloxy-DMT 5,6-diBr-DMT 5-AcO-DMT 5-Bromo-DMT 5-MeO-2,N,N-TMT 5-MeO-4,N,N-TMT 5-MeO-α,N,N-TMT 5-MeO-DMT 5-N,N-TMT 7,N,N-TMT α,N,N-TMT (Bufotenin) 5-HO-DMT DMT Norbaeocystin (Psilocin) 4-HO-DMT (Psilocybin) 4-PO-DMT

*-DET	(Ethacetin) 4-AcO-DET (Ethocin) 4-HO-DET 5-MeO-DET (T-9) DET (Ethocybin) 4-PO-DET

*-DPT	(Depracetin) 4-AcO-DPT (Deprocin) 4-HO-DPT 5-MeO-DPT (The Light) DPT

*-DiPT	1-Me-5-MeO-DiPT (Ipracetin) 4-AcO-DiPT (Iprocin) 4-HO-DiPT (Foxy Methoxy) 5-MeO-DiPT DiPT

*-DALT	(Daltocin) 4-HO-DALT (Daltacetin) 4-AcO-DALT 5-MeO-DALT DALT

*-MET	(Metocin) 4-HO-MET (Metocetin) 4-AcO-MET 5-MeO-MET MET

*-MiPT	(Mipracetin) 4-AcO-MiPT (Miprocin) 4-HO-MiPT 5-Me-MiPT (Moxy) 5-MeO-MiPT MiPT

Subst. Ibogamine	Ibogaine Noribogaine Voacangine

Others	4-HO-DBT 4-HO-EPT 4-HO-McPT (Lucigenol) 4-HO-MPMI (Meprocin) 4-HO-MPT 5-MeO-EiPT 5-MeO-MALT 5-MeO-MPMI Aeruginascin Baeocystin DBT DCPT EiPT EPT MPT PiPT

Others

5-MeO-DiBF
AL-38022A
ALPHA
Dimemebfe
Efavirenz
Lorcaserin
M-ALPHA
RH-34
Also empathogens in general (e. g.: 5-APB, 5-MAPB, 6-APB and other substituted benzofurans, MDAI, MDMA).

Dissociatives
(NMDAR
antagonists)

Arylcyclo‐ hexylamines	2-Fluorodeschloroketamine 3-HO-PCP 3-MeO-PCE 3-MeO-PCMo 3-MeO-PCP 4-MeO-PCP Arketamine Deschloroketamine Dieticyclidine Esketamine Ethketamine Eticyclidine Gacyclidine Ketamine Methoxetamine Methoxmetamine Methoxyketamine Norketamine PCPr PCP Rolicyclidine Tenocyclidine Tiletamine

Morphinans	Dextrallorphan Dextromethorphan Dextrorphan Racemethorphan Racemorphan

Diarylethylamines	Diphenidine Ephenidine Fluorolintane Methoxphenidine

Others	2-MDP 8A-PDHQ Aptiganel Budipine Delucemine Dexoxadrol Dizocilpine Etoxadrol Ibogaine Midafotel NEFA Neramexane Nitrous oxide Noribogaine Perzinfotel Remacemide Selfotel Xenon

Deliriants
(mAChR
antagonists)

Others

Cannabinoids
(CB₁ agonists)

Natural	Cannabinol THC (Dronabinol) THCV

Synthetic	4-HTMPIPO 5F-AB-FUPPYCA 5F-AB-PINACA 5F-ADB 5F-ADB-PINACA 5F-ADBICA 5F-AMB 5F-APINACA 5F-CUMYL-PINACA 5F-NNE1 5F-PB-22 5F-SDB-006 A-796,260 A-836,339 AB-001 AB-005 AB-CHFUPYCA AB-CHMINACA AB-FUBINACA AB-PINACA ADAMANTYL-THPINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADBICA ADSB-FUB-187 AM-630 AM-679 AM-694 AM-1220 AM-1221 AM-1235 AM-1241 AM-1248 AM-2201 AM-2232 AM-2233 AMB-FUBINACA APICA APINACA APP-FUBINACA CB-13 CP 47,497 CP 55,244 CP 55,940 CUMYL-PICA CUMYL-PINACA CUMYL-THPINACA DMHP EAM-2201 FAB-144 FDU-PB-22 FUB-144 FUB-APINACA FUB-JWH-018 FUB-PB-22 FUBIMINA HU-210 HU-308 JWH-007 JWH-015 JWH-018 JWH-019 JWH-030 JWH-073 JWH-081 JWH-098 JWH-116 JWH-122 JWH-149 JWH-167 JWH-182 JWH-193 JWH-198 JWH-200 JWH-203 JWH-210 JWH-250 JWH-251 JWH-398 JWH-424 JTE 7-31 JTE-907 Levonantradol MDMB-CHMICA MDMB-CHMINACA MDMB-FUBINACA MEPIRAPIM MAM-2201 MDA-19 MN-18 MN-25 NESS-0327 NESS-040C5 Nabilone Nabitan NM-2201 NNE1 Org 28611 Parahexyl PTI-1 PTI-2 PX-1 PX-2 PX-3 QUCHIC QUPIC RCS-4 RCS-8 SDB-005 SDB-006 STS-135 THC-O-acetate THC-O-phosphate THJ-018 THJ-2201 UR-144 WIN 55,212-2 XLR-11

D₂ agonists

Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
Memantine
Nuciferine
Pergolide
Phenethylamine
Piribedil
Pramipexole
Ropinirole
Rotigotine
Salvinorin A
Also indirect D₂ agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).

GABA_A
enhancers

Inhalants
(Mixed MOA)

κOR agonists

Others

References

↑ http://documents.theblackvault.com/documents/mkultra/MKULTRA1/DOC_0000017481/0000017481_0021.TIF

This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.